KEROS THERAPEUTICS INC (KROS)
US4923271013 - Common Stock
KEROS THERAPEUTICS INC
NASDAQ:KROS (5/3/2024, 7:02:33 PM)
After market: 60.57 0 (0%)60.57
+3.47 (+6.08%)
Company Profile
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 129 full-time employees. The company went IPO on 2020-04-08. The firm is focused on the discovery, development and commercialization of treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need. Its protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. Its lead small molecule product candidate, KER-047, is being developed for the treatment of functional iron deficiency. Its third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, and for the treatment of cardiovascular disorders. Its KER-050 is an engineered ligand trap comprised of a modified ligand-binding domain of the transforming growth factor-beta (TGF-B) receptor. The company is designed to raise red blood cell and platelet production.
Company Info
KEROS THERAPEUTICS INC
1050 Waltham Street, Suite 302
Lexington MASSACHUSETTS 02421
P: 16173146297
CEO: Jasbir Seehra
Employees: 129
Website: https://www.kerostx.com/
KROS News
LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company...
2 months ago - Seeking Alpha(NASDAQ:KROS)Keros Therapeutics reports Q4 GAAP EPS of -$1.34, beating expectations by $0.04, with revenue of $0.14M.
LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage...
3 months ago - Market News VideoCommit To Buy Keros Therapeutics At $50, Earn 18.5% Annualized Using OptionsLEXINGTON, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company...
4 months ago - Seeking AlphaKeros Therapeutics prices upsized stock offering to raise $140 millionKeros Therapeutics (KROS) on Wednesday priced an underwritten public offering of 3.5 million shares of its common stock at $40.00 per share, for an expected gross proceeds of $140.0 million.
KROS Twits
Here you can normally see the latest stock twits on KROS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
